Overall, these results demonstrated that HNSCC cell lines with different sensitivity to cetuximab contain a high percentage of EGFR‐, HER2‐, and HER3‐positive cells and that these receptors are generally highly expressed on these positive cells. Here, ERBB2 is linked to head and neck squamous cell carcinoma.